Abstract | OBJECTIVES: METHODS: Eight patients with autosomal dominant cerebellar ataxia were given intravenous piracetam 60 g/day by a structured protocol for 14 days. The baseline and end-of-the study evaluations were based on the International Cooperative Ataxia Rating Scale. RESULTS: Statistical analysis demonstrated a significant improvement in the patients' total score (P = 0.018) and a subscale analysis showed statistical significance for only the posture and gait disturbances item (P = 0.018). CONCLUSION: This study is providing good clinical observation in favour of high dose piracetam infusion to reduce the disability of the patients by improving their gait ataxia.
|
Authors | D Ince Gunal, K Agan, N Afsar, D Borucu, O Us |
Journal | Journal of clinical pharmacy and therapeutics
(J Clin Pharm Ther)
Vol. 33
Issue 2
Pg. 175-8
(Apr 2008)
ISSN: 1365-2710 [Electronic] England |
PMID | 18315783
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Neuroprotective Agents
- Piracetam
|
Topics |
- Adult
- Aged
- Cerebellar Ataxia
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Neuroprotective Agents
(therapeutic use)
- Piracetam
(therapeutic use)
- Treatment Outcome
|